ArticleJournal for immunotherapy of cancer2023
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas.
Nicholas P Tschernia et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this paperpooled itcites it